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Radiation therapy is one of the most effective tools in the treatment of malignant 
tumours and is applied to both adults and children who suffer from primary or 
metastatic brain tumours. However, in the treatment of paediatric malignancies is 
responsible of severe late effects, such as hormonal imbalances, growth retardation and 
cognitive decline. Alleviating these late effects could have a huge impact in the quality 
of life of the increasing number of children who survive their cancer. 
Our aim was to investigate the possible protective effect in the brain of montelukast 
(MTK). Female mice received a double dose of 4 Gy to the whole brain separated by 12 
h in between on postnatal day 21 (P21) and were sacrificed 12 days later. For cell count 
we looked at oligodendrocytes (Olig2+ cells) in the corpus callosum (CC) and at 
proliferating cells (Ki-67+ cells) in the hippocampus (HC). A difference after irradiation 
(IR) was observed in the Olig2+ count, where non-IR mice showed higher numbers of 
oligodendrocytes compared with IR animals (P < 0.01). IR also affected the density of 
these cells (P < 0.05), but in no case was there a significant difference between IR NaCl 
and IR MTK groups. In the HC there was a significant reduction of MTK cells versus NaCl 
control cells (P < 0.05). Therefore, further studies are needed. In conclusion, we show 
that MTK does not protect neither against Olig2+ cell loss in the CC nor Ki-67+ loss in the 




La radioteràpia és una de les eines més efectives en el tractament de tumors malignes i 
s’aplica tant a adults com a infants que pateixen tumors primaris o metastàtics. No 
obstant, en el tractament pediàtric és responsable d’efectes retardats severs com 
descompensacions hormonals, retard del creixement i declivi cognitiu. Alleugerar 
aquests efectes podria tenir un gran impacte en la qualitat de vida del creixent nombre 




El nostre objectiu era investigar el possible efecte protector en el cervell del montelukast 
(MTK). Ratolins femella van rebre una doble dosis de 4 Gy a tot el cervell separada per 
12 h entremig, en el dia postnatal 21 (P21) i van ser sacrificades 12 dies després. Pel 
comptatge de cèl·lules vam mirar el oligodendròcits (Olig2+ cells) en el cos callós (CC) i 
les cèl·lules proliferatives (cèl·lules Ki-67+) a l’hipocamp (HC). Es va observar una 
diferència després de la irradiació (IR) en el comptatge d’Olig2+ la qual mostrava que els 
ratolins no irradiats tenien un major nombre d’oligodendròcits comparat amb els 
animals irradiats (P < 0.01). La IR també va afectar la densitat d’aquestes cèl·lules (P < 
0.05), però en cap cas va haver-hi una diferència significativa entre els grups IR NaCl i IR 
MTK. A l’HC hi havia una reducció significativa de cèl·lules MTK versus cèl·lules NaCl dels 
grups de control (P < 0.05). Per tant, es requereixen més estudis. Com a conclusió, 
mostrem que el MTK no protegeix ni contra la pèrdua de cèl·lules Olig2+ en el CC ni 
contra la pèrdua de cèl·lules Ki-67+ en l’HC després de la radioteràpia i que el MTK 















2. INTEGRATION OF THE THREE DIFFERENT SCOPES 
This experimental project integrates three different scopes: pharmacology and 
therapeutics, physiology and physiopathology and cell biology.  
As will be seen below, this project is divided in two parts: a bibliographic review and an 
experimental part. The experimental part consists in testing mice to check whether the 
drug montelukast is able to protect the brain from irradiated neurotoxicity, for that was 
necessary the knowledge of its distribution and mechanism of action thus pharmacology 
and therapeutics is the main scope. 
Physiology and physiopathology scope is shown in the description of the structures and 
the cells from the brain. Finally, cell biology is important to understand how 

















3.1. Brain tumours in childhood 
Cancer is rare before the age of 20 (1), but out of all paediatric tumours, primary 
tumours of the central nervous system (CNS) are the second most common cancer in 
childhood (0 -14 years) comprising over 20% of cases and the third most common cancer 
type in adolescence ( ̴10% of cases) in Europe (2). 
Children diagnosed with CNS malignancies traditionally have had poor survival rates. 
Improvements in neurosurgical technique, supportive care, radiotherapy (RT) and the 
use of combination chemotherapy have improved 5-year survival for these patients. 
However, these treatments are associated with risk of long-term morbidity (3). Up to 
80% of paediatric brain tumour survivors experience significant, life-long sequelae from 
treatment which do not only concern health and psychological aspects but also social 
challenges (4); for most of them, this cognitive deterioration leads to the need for special 
education (5).  
 
3.2. Treatments 
Treatment of brain and other CNS tumours depend on the histology, location, size, and 
other prognostic factors. Whenever possible, surgery is performed to remove as much 
of the tumour as possible. Subsequent chemotherapy and/or RT depend on the type of 
tumour, and optimal therapy requires coordinated efforts of paediatric specialists in 




Most surgery procedures are performed with the intention to procure tissue to establish 
the histological diagnosis, to alleviate mass effect on the surrounding structures, and to 





Traditionally, the types of chemotherapeutic agents used in patients with brain tumours 
have included microtubule disrupting drugs (e.g., vincristine) which interfere in 
microtubule dynamics and stop cell division process (8), and alkylating agents which 
exert cytotoxic effects by transferring alkyl groups to DNA, thereby damaging the DNA 
and interfering with DNA transcription and cell division (9). Within the latter group are 
included platinum analogues (cisplatin and carboplatin), also nitrosoureas (e.g., 
carmustine, lomustine), cyclophosphamide, and ifosfamide, and more recently 
temozolomide. Inhibitors of topoisomerase I and II (camptothecins, etoposide) interfere 
with the action of these enzymes and impede the changes in the DNA helix (9), and have 
also been used either as single agents or in combination with alkylating drugs (10). 
The main limitation of these drugs is their limited ability to cross the blood brain barrier 
(BBB). The concentrations within the CNS depend on multiple factors, including the 
permeability of the BBB to the chemotherapeutic agent, the extent to which the drug is 
actively transported out of the brain, and the drug volume of distribution in the brain 
parenchyma (11).  
If they get through the BBB there is a risk of side effects as it has been demonstrated 
that many chemotherapeutic agents affect the precursor cells that contribute to 
hippocampal neurogenesis (the generation of new neurons) (12).  
 
3.2.3. Radiotherapy 
Despite the late effects of RT, it remains a major treatment modality for primary and 
metastatic neoplasms located in the CNS for both adults and children (13)  because it is 
one of the most effective tools in the treatment of malignant tumours (14) (15). 
However, cranial radiotherapy (CRT), particularly when used in very young children, can 
result in neurocognitive deficits. For this reason, treatment protocols for patients with 
CNS tumours have been modified so that children aged younger than three years usually 
receive chemotherapy first in order to delay or reduce the radiation (6).  
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The success of RT depends on the total radiation dose and this one is limited by the 
tolerance of normal tissues surrounding the tumours since the purpose is to keep them 
healthful (16). Normal tissues show a narrow range of radiosensitivity while cells from 
human tumours show a very broad range of D0 (dose required to reduce the fraction of 
cells surviving to 37%) values, hence, if the dose is too low no cells will be affected and, 
conversely, if the dose is too high all healthy and tumour cells will die (17). Ionizing 
radiation induces different kind of damage to the DNA (18). Normal cells have evolved 
sensors and pathways to respond to each one of these injuries but tumour cells cannot 
because they have their recombinational repair pathway altered (19). Besides, the 
radiosensitivity of cells varies considerably as they pass through the cell cycle and there 
seems to be a general tendency for cells to be more sensitive at or close to mitosis (20) 
(21).  
The major reason why in the immature brain of both humans and rodents irradiation 
(IR) has more devastating and long-lasting effects than to older brains it is mainly due to 
its high content of progenitor cells, and that IR induces both an acute loss of progenitors 
through apoptosis and a perturbed microenvironment incompatible with normal 
proliferation and differentiation leading to a limited potential for repopulation (22).  
                                                                          
3.3. Effects of irradiation 
CRT during childhood can cause adverse side effects such as hormonal imbalances, 
growth retardation and persistent impaired learning and memory function. Risk factors 
are age at treatment, radiation quality, dose per fraction, volume treated, total dose and 
gender, where girls suffer more severe late effects than boys, although the reason for 
this difference is yet unknown (23) (24). 
Referring to the neurological side-effects (Figure 1), it is possible to differentiate 
between acute (during radiation), early-delayed (up to 6 months post-irradiation), and 
late-delayed (more than 6 months to several years post-irradiation) (25). Acute brain 
injury is rare with current RT techniques. Early delayed brain injury can involve transient 
demyelination with somnolence, which is mainly seen in paediatric population but can 
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also affect adult patients in the first 2 months after therapy. Both of these injuries are 
usually reversible and resolve spontaneously. In contrast, late delayed brain injury which 
includes vascular abnormalities, demyelination, reduced neurogenesis, and white 
matter necrosis are irreversible and progressive (26) (27).  
 
Figure 1. Symptoms of radiation-induced CNS. CNS manifestations after therapeutic intracranial IR follow 
this generally accepted time course (26). 
 
3.4. Oligodendrocytes  
OLs are the myelinating glial cells of the CNS (28). Most of them are located in white 
matter where their primary role is to form myelin. The myelin sheath is a membrane 
that surrounds axons and promotes the fast and efficient conductions of electrical 
impulse along those axons. The myelination of the developing brain is essential for the 
normal functioning of the mature CNS; disruption of CNS myelin lead to severe 
functional deficits and frequently a reduction in life span (29). Moreover, OLs accomplish 
distinct functional roles such as maintenance of axonal integrity and participation in 
signalling networks with neurons (30).  
Due to the combination of a high metabolic rate with its toxic by-products, high 
intracellular iron, and low concentration of the antioxidative glutathione, OLs are 
particularly vulnerable to oxidative damage (31). For these reasons, OLs are thought to 
be the most radiation-sensitive glial cell type in the CNS. In rodents, the number of OLs 
reduces throughout the brain within a few hours of IR. Oligodendrocyte precursor cells 
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are widely distributed throughout the CNS (32) and they are rather susceptible to IR (20) 
(21). The majority (75%) of cells capable of division in the adult brain are 
oligodendrocyte precursor cells, this means they will be proliferating while getting IR. 
Loss of these cells is presumed to decrease the replacement of OLs (26). Although most 
major tracts are significantly myelinated by early childhood, later-maturing myelin 
sheaths continue to myelinate into the second and third decades of life and there is a 
significant remodelling of grey and white matter (33), pointing that OLs are still needed.  
 
3.5. Corpus callosum 
The corpus callosum (CC) is the largest white matter commissure and it is situated in the 
centre of the human brain (Figure 2). Therefore, its role is essential to the integration of 
the information between left and right cerebral hemispheres. In the human brain, the 
development of the CC is almost completed within the first four years in a child’s life 
(34). However, its volume continues to increase through adolescence driven by 
myelination of the interhemispheric axons that compose the CC (35). Over adulthood, 
the structure may expand and decrease in size in different regions, strongly suggesting 
an ongoing process of remodelling (36). 
 
Figure 2. Schematic illustration of a sagittal rodent brain with the CC outlined in gray and below it the HC 
in black (23). 
 
The CC is affected in children subjected to CRT, with the greatest effects observed in the 
most posterior subregions (isthmus and splenium). In the normal brain, CC continues to 
develop in an anterior to posterior pattern well into the second decade of life but in the 
irradiated brain, depending on the exposure, there are subregion-specific changes. 




The hippocampus (HC) is an elongated structure in the medial temporal lobe (38) with a 
laminated structure. It consists of four parts: the dentate gyrus (DG); the cornu ammonis 
(CA) (subdivided in CA1, CA2, CA3 and CA4); the presubiculum; and the subiculum (39). 
Neurogenesis occurs throughout life mainly in two regions, the subventricular zone in 
the lateral walls of the lateral ventricles and in a narrow band of tissue in the DG called 
the subgranular zone (SGZ) (Figure 3) (40). Neural stem cells in the DG are self-renewing 
cells which generate neurons, astrocytes, oligodendrocytes, and produce new dentate 
granule neurons (the principal cell type which constitutes the principal layer in the DG 
(41)) in all vertebrates studied, including humans (42).  
 
Figure 3. A representative picture of the dentate gyrus of a mouse that shows the GCL outlined in 
discontinuous lines and the SGZ painted in black (picture taken in 5x). 
 
The study of the epileptic patient H.M. who followed surgical removal of most of both 
of his medial temporal lobes as an experimental procedure to stop his seizures build the 
main theories about memory organization (43) . H.M. was incapable of forming new 
memories; he could not convert immediate memory into stable long-term memory, but 
surprisingly he could recall events and faces from before his surgery. This finding implied 
that the medial temporal lobe is not the ultimate storage site for previously acquired 
knowledge but memory can be supported by the neocortex and become independent 
of the first structure. With H.M. we also learn the term declarative memory which is 
what is meant when the word “memory” is used in everyday language and is dependent 
on the medial temporal lobe (44). The representations of facts (semantic memory) and 
events (episodic memory) that can be recalled consciously and verbalized constitute the 
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declarative memory (19). Many studies have identified that the HC plays a critical role 
in episodic memory, our capacity to remember everyday events in order (45); and also 
is involved in particular aspects of the acquisition of semantic knowledge (46). But still 
the major finding thanks to H.M. is the absolute need of a functioning HC to be able to 




hydroxy-1-methylethyl)phenyl)propyl)thiol]-methyl)cyclopropane acetate blocks the 
pro-inflammatory action of leukotriene D4 (LTD4) and it is approved for the maintenance 
treatment of asthma and to relieve symptoms of seasonal allergies. It acts by inhibiting 
neutrophil infiltration, balancing oxidant-antioxidant status, and regulating the 
generation of inflammatory mediators (47). LTD4 is a pro-inflammatory mediator that 
promote vasoconstriction and increase vascular permeability; it is present in the CNS 
and it has been reported that causes BBB disruption and brain edema via the cysteinyl 
leukotriene receptor 1 (CysLT1R) (48).  
Probably due to its once daily dosing schedule (10 mg/day), safety and efficacy profiles 
MTK is the most prescribed CysLT1R antagonist in Europe and the USA (49) and it has 
the same efficacy as pranlukast 225 mg twice daily and zafirlukast 40 mg twice daily. 
Moreover, there is no evidence of interaction with food unlike zafirlukast (50) (51).  
Until a few years ago, only minimal distribution of MTK across the BBB had been 
described by the Food and Drug Administration (50), but in a study from Marschallinger 
et al. (52) they detected in a human subject taking 10 mg MTK per day the drug in the 
serum and in the cerebrospinal fluid (CSF). In addition, a re-analysis of the original CNS 
pharmacology data of MTK from the Food and Drug Administration indicates a 
significant BBB penetrance of the drug. Most remarkably, while in plasma and other 
organs MTK levels strongly decreased within 24h, the amount of drug in the brain 
increased and it was even higher than in plasma, suggesting the existence of an active 
transport mechanism through the BBB. This data proposes that the standard dose 10 
mg per day in humans is sufficient to reach a therapeutic dose in the CSF. 
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In this same studio from Marschallinger et al. (52) they demonstrated that MTK reduces 
neuroinflammation, restores BBB integritiy and increases neurogenesis, specifically in 
the brain of old rats antagonizing the CysLT1R and G protein-couple receptor 17 
(GPR17). Although both receptors are found in the CNS, CysLTR1 expression was 
primarily found both in vitro and in vivo on non-neuronal cells, while GPR17 was 
predominantly present on cells of the neuronal lineage, suggesting that the MTK 
induced effects on neurogenesis might most likely be mediated through inhibition of 



















4. AIM OF THE WORK 
The following project will investigate if a pharmacological intervention using MTK 
protect the developing brain from radiation-induced neurotoxicity. 
 
Specific aims of the thesis 
I. To investigate MTK’s effects on: 
 
a) Survival of OLs in the CC after CIR. 
 

















5. MATERIAL AND METHODS 
The practical part of this project was realized as my Erasmus internship at the 
Department of Pharmacology in the Institute of Neuroscience and Physiology at the 
Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. I joined the 
group of “Neurotoxicity in cancer survivors” whom principal investigator is Marie Kalm 
(PhD, Postdoc) and it is integrated also by Martina Boström (PhD, Postdoc), Erik 
Fernström (MD, doctoral student), Yohanna Eriksson (Msc, doctoral student) and Rita 
Grandér (BMA).  
 
5.1. Animals 
Female C57BL/6J mice were used (Charles River Laboratories, Sulzfeld, Germany). 
Animals were kept on 12-h dark/light cycle with food and water ad libitum. All 
experiments were approved by the Gothenburg committee of the Swedish Animal 
Welfare Agency (72-2015). 
 
5.2. Montelukast treatment  
Montelukast sodium powder (Sigma, St. Louis, MO, USA), dissolved in ethanol for 
maximum solubility and then further diluted with a 0.9% saline (NaCl) solution, was 
administered daily per intraperitoneal injection (i.p.) at a dose of 10 mg kg-1 of body 
weight for 14 days to young mice (N = 4 - 9 mice/group), starting 2 days before cranial 
irradiation (CIR) (the timeline of the study is presented in Figure 4). The animals were 
treated with MTK at a dose that pharmacologically resembles the one that is approved 
for its use in humans and that is enough to reach a therapeutic effect in the CSF (52). 
Age-matched group control mice received i.p. injections of the vehicle solution (10% 
ethanol in 0.9% saline solution) for 14 days, also starting 2 days before CIR. Weight and 




Criteria for early termination of treatment were obvious signs of pains, apathy and loss 
of weight more than 15%.  
 
Figure 4. Outline of the experimental design. The animals were IR on postnatal day 21 (P21). The mice 
were injected during all the days of the experiment with either MTK or NaCl and sacrificed 12 days after 
IR. 
 
5.3. Irradiation procedure 
For the IR procedure, a linear accelerator (Varian Clinic 600 CD; Radiation Oncology 
Systems LLC San Diego, CA, USA) with a 4 MV nominal photon energy and a dose rate of 
2.3 Gray (Gy) per minute was used. 
Mice were postnatal day 21 (P21) when irradiated which is equivalent to a young child 
(53). They were anesthetized with isoflurane (0.6 - 4%) via a mask during the procedure 
and then placed in prone position on a polystyrene bed. To obtain an even radiation 
dose throughout the underlying tissue, the head was covered by a 1 cm tissue equivalent 
material. The whole brain was irradiated with an IR field of 2 x 2 cm. The source to skin 
distance was   ̴ 99.5 cm. A dose of 4 Gy was administered twice, with an interval of 12 h 
between fractions. A double dose of 4 Gy is clinically relevant and similar to a total dose 
of 18 Gy (54). This dose represents a clinically relevant dose, equivalent to the total dose 
used in treatment protocols for prophylactic CIR in selected cases of childhood acute 
lymphatic leukaemia (18 GY). The doses used for paediatric brain tumours are often 
higher, up to 55 Gy. The sham control animals were anesthetized but not subjected to 
irradiation (55). After IR the pups were returned to their dams. Animals were euthanized 




5.4. Tissue preparation 
Animals were deeply anesthetized with sodium pentobarbital (Pentothal®; Electra-box 
Pharma, Tyresö, Sweden) before being transcardially perfused with a 6% formaldehyde 
solution buffered with sodium phosphate at pH 7.4 and stabilized with methanol 
(HistofixTM; Histolab Products AB, Sweden). The brains were immersion-fixed in Histofix 
for 24 h after perfusion; this was changed to 30% sucrose solution containing 100 mM 
phosphate buffer, pH 7.5. The right hemisphere was cut into 25 µm sagittal sections in 
a series of 12, using a sliding microtome manufacturer (SM2010R, Leica Microsystems 
Wetzlar, Germany). The sections were stored in a cryoprotection solution, containing 
25% ethylene glycol and 25% glycerol, at 4 ̊C until staining. 
 
5.5. Immunohistochemistry 
All staining was performed using free-floating staining protocols. Sections were rinsed 
three times in Tris-buffered saline (TBS) and incubated in 0.6% hydrogen peroxide (H2O2) 
in TBS for 30 min to block endogenous peroxidases and minimize unspecific staining. 
Sections where then rinsed three times in TBS and incubated for 30 min in 3% donkey 
serum (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) dissolved in 
TBS containing 0.1% Triton X-100 (Merck KGaA, Darmstadt, Germany) to block 
nonspecific binding. The sections were incubated overnight at 4˚C with primary 
antibodies (Table 1). The next day, the sections were washed in TBS and a biotinylated 
secondary antibody was added (donkey anti-rabbit, 1:1000, Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA, USA) and incubated at room temperature for 60 min. 
Sections were then rinsed three times with TBS and incubated with Avidin-Biotin-
Peroxidase (10 µl/ml TBS of A and B, Vectastain Elite ABC Kit, Vector Laboratories, 
Burlingame, CA, USA) for 1 hour to let the ABP complex attach to the secondary 
antibodies. The sections were washed three times and then the staining was developed 
in 3,3’-diaminobenzidine (DAB, Saveen Werner AB, Malmö, Sweden), diluted in TBS with 
hydrogen peroxide (H2O2) and nickel chloride (NiCl2) for enhancement of the reaction. 
To stop the reaction, the sections were washed several times in tap water and then 
placed in TBS until mounting from 0,1M phosphate buffer, pH 7.5, on glass slides. 
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Sections were left to dry overnight and then cover slipped with X-Tra-Kitt (Medite 
GmbH, Burgdorf, Germany). 
Antibody Dilution Company 
Rabbit anti-Olig2 1:500 Abcam 
Rabbit anti-Ki-67 1:1000 Abcam 
   
Table 1. List of primary antibodies. 
 
5.6. Olig2 and Ki-67 markers 
Oligodendrocyte transcription factor 2 (Olig2) is a basic helix-loop-helix transcription 
factor necessary for oligodendroglial development (56). It is one of the most consistent 
markers of the OL lineage, being expressed at all stages and having a clear role in OL 
progenitor cells specification in most regions of the CNS. However, its function during 
later stages of development is yet unclear (32). 
Ki-67 is an excellent marker to determine the growth fraction of a given cell population 
because its expression is strictly associated with cell proliferation. The Ki-67 antibody is 
reactive with a nuclear structure present during all active phases of the cell cycle (G1, S, 
G2, M) and is absent from resting cells (G0) (14). 
 
5.7. Cell counting and volume assessment  
For quantification of Olig2+ cells in the CC, analyses were performed blinded on coded 
slides. Olig2+ cells were counted throughout the CC in all sections containing a clearly 
separated/divided dorsal and ventral HC (see Figure 5 for a representative picture), 
using Stereo Investigator program (MBF Bioscience Inc., Williston, VT, USA). The CC was 
visualised at 5x and then traced at 10x magnifications on sagittal cut sections using a 
Leica DM6000B microscope (Leica Microsystems, Wetzlar, Germany). The GCL volume 
was measured as the area between the hilus and the molecular layer. The inner length 
of the GCL was measured as the border between the GCL and the hilus. Ki-67+ cells were 
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counted only in the SGZ, defined as ranging from thee cell layers into the GCL to two 
layers into the hilus. Micrographs were taken with a Microfire camera (Optronics, 
Goleta, CA, USA). All immunopositive cells in the CC and in the GCL were counted in 
every 12th section in the right hemisphere in 20x magnification, resulting in 4-7 sections 
per animal. Area (mm2), volume (mm3), total Olig2+ cells, total Ki-67+ cells and density 
(cells/mm3) were analysed. Total volumes were calculated according to the Cavalieri 
principle, using the following formula: V = SA x P x T, where V is the total volume, SA is 
the sum of area measurement, P is the inverse of the sampling fraction and T is the 
sections thickness. The total number of cells was obtained by multiplying the number of 
counted cells with the sampling fraction.  
 
Figure 5. A representative picture of a sagittally cut section of a mouse brain chosen for counting (image 
taken in 1.25x magnification). The CC is outlined in red and the GCL in green. 
 
5.8. Statistical analysis 
All results are plotted as mean ± standard error of the mean (SEM), with P < 0.05 
considered statistically significant. Statistical analyses were performed using GraphPad 
Prism 5.0 (GraphPad Software, La Jolla, CA, USA). Statistical comparisons were 
performed with an unpaired, two-way analysis of variance (two-way ANOVA). Significant 
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differences were analysed using a multiple comparison adjustment of P values (Tukey’s 























6. RESULTS  
Survival of cells in the CC in the young mouse brain following CIR. Oligodendrocytes in 
the CC: Olig2 was used as a marker of OL in the CC. Statistical comparison by two-way 
Anova revealed significant changes after IR in the Olig2+ count, where non-IR animals 
showed higher numbers of OLs compared with IR animals (F1,21 = 10.44, P = 0.004, Figure 
6b). Post-hoc Tukey revealed no significant differences between groups. Overall IR 
decreased the number of OLs by 43% in NaCl treated animals and by 50% in MTK 
animals. There was no significant effect from MTK in the total number of cells.  
 
Figure 6. (a) Olig2 immunostaining in the CC of a mouse (black arrowheads point toward representative 
Olig2+ cells) (image taken in 20x magnification). (b) Number of Olig2+ cells in the CC. Data are shown as 
mean ± S.E.M (N = 4-9 mice/group). Two-way Anova results are indicated on the graphs: ** P < 0.01 for 
irradiation.   
 
Volume of the CC following CIR. The CC was traced in all mice. Two-way Anova results 
show no difference in volume between groups (F1, 21 = 1.669, P = 0.2105 for irradiation; 
F1, 21 = 0.0001086, P = 0.9918 for drug treatment; overall statistical comparisons by two-
way Anova followed by post-hoc Tukey test; Figure 7a). 
Density of the CC following CIR. Analysis of data displays a significant difference (F1,21 = 
7.226, P = 0.0138, Figure 7b) where IR animals have lower Olig2+ cells/mm3 than control 
animals. The irradiated NaCl group had 33% less OLs compared to the NaCl control 
group. For the MTK treated group the difference was 45%. Post-hoc Tukey did not show 





Figure 7. a) Shows total volume (mm3) of the CC. (b) Shows a quantifications of Olig2+ cells/mm3 in the 
CC. All data shown as mean ± S.E.M (N = 4-9 mice/group). Two-way Anova results are indicated on the 
graphs: * P < 0.05 for irradiation. 
 
Proliferation of cells in the GCL in the young mouse brain following CIR. Proliferating 
cells in the DG: marker Ki-67 was used followed by quantification of labelled cells. 
Analysis of the total cells shows a significant difference (F1,22 = 5.434, P = 0.0293, Figure 
8b) between NaCl and MTK. Post-hoc Tukey analysis revealed a significant difference 
specifically between MTK control and NaCl control. There was a difference of 52% less 
Ki-67+ cells in MTK control mice than in NaCl control group. 
Volume of the GCL following CIR. After measuring the volume of the GCL the double-
way Anova shows a significant difference in the irradiated group (F1,21 = 7.621, P = 
0.0114, Figure 8c). Post hoc analysis reported a difference between control and 
irradiated MTK treated mice. The reduction for MTK group was of 33% whereas for NaCl 
was just of 8%. 
Density of the GCL following CIR. The density of the Ki-67+ cells in the GCL follows the 
same pattern as for total number of cells, even if the differences did not reach a 
significant level (F1,22 = 0.06932, P = 0.7948 for drug treatment; F1,22 = 3.654, P = 0.0690 
for irradiation; statistical comparisons by two-way Anova followed by post-hoc Tukey 
test; Figure 8d). Interestingly, the density was a 30% higher after IR in the treatment 





Figure 8. (a) Ki-67 immunostaining in the DG of a mouse (black arrowheads point toward representative 
Ki-67+ cells) (image taken in 10x magnification). (b) Number of Ki-67+ cells in the GCL. (c) Shows total 
volume (mm3) of the GCL. (d) Shows a quantifications of Ki-67+ cells/mm3 in the GCL. Two-way Anova 
showed a significant effect of the variable drug treatment in the number of Ki-67+ cells (F1,22 = 5.434, P = 
0.0293) and a significant difference for irradiation in the total volume (F1,22 = 7.621, P = 0.0114). Data are 
shown as mean ± S.E.M (N = 4-9 mice/group). Post-hoc Tukey test results are indicated on the graphs: *P 













OLs and the myelin sheaths they form belong to the most vulnerable cellular 
components of the CNS. Due to the combination of a high metabolic rate with its toxic 
byproducts, high intracellular iron, and low concentration of the antioxidative 
glutathione, OLs are particularly vulnerable to oxidative damage. Hence, oxidative 
damage is a common contributor to OL loss under many pathological conditions (31). 
Further, DNA damage is induced directly by ionization of DNA or indirectly by generation 
of free radicals, resulting in apoptosis and loss of cells (22). After brain radiotherapy, 
oxidative stress is thought to result from an inflammatory response where IR activates 
microglia and causes immune cells to infiltrate the brain. These cells then generate 
reactive oxygen species which in turn activate more microglia and activate more 
immune cells that can maintain or increase the level of oxidative stress (27). The 
susceptibility of the myelin membrane to oxidative impairment may account for the 
predilection of radiation injury for white matter (13). OL loss can also occur as a result 
of exposure to inflammatory cytokines (31), which are shown to increase acutely in 
response to CRT (5). All this together explains the reduction of cells seen after IR in the 
CC (Figure 6b).  
The DG is also known to be affected by IR, in particular the proliferating cells in the SGZ 
of the GCL, leading to a limited capacity for repopulation or regeneration. This may occur 
in at least three ways: (i) through cell death (apoptosis or mitotic catastrophe), (ii) 
through decrease proliferation and (iii) through perturbed precursor cell proliferation 
(57). Loss of proliferating neural stem and progenitor cells results in impaired growth 
and a smaller GCL volume than in non-irradiated brains (Figure 8c) (58).  
Leukotrienes (LT) levels are typically increased in brains affected by neurodegenerative 
diseases. The elevated levels of 5-lipoxygenase and LTs cause post-inflammatory brain 
damage by mediating the generation of reactive oxygen species, resulting in a higher 
expression of inflammatory mediators such as tumour necrosis factor (TNF) alpha and 
interleukin-1 (IL-1) beta. This might consequently result in reduced neurogenesis, as TNF 
alpha and IL-1 beta signalling is known to inhibit neural stem cell proliferation and 
neurogenesis (59). Taking into account the mechanism of action of MTK, the anti-
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inflammatory effect by MTK could potentially protect against OL cell death, therefore it 
was expected to see a higher number of Olig2+ cells in the IR animals treated with MTK 
than in NaCl animals. Although there is no significant difference, there are 16% and 21% 
less cells in MTK IR mice compared with NaCl IR in the CC and GCL respectively (Figure 
6b) so it seems like the treatment is not working for preventing cell death. Surprisingly, 
we also observed differences between NaCl and MTK control animals in the GCL 
counting (Figure 8b). Apparently, MTK was inhibiting proliferation of cells. This 
correlates with another finding from the group (unpublished data) where they found a 
reduction in the number of microglia cells in both control and irradiated MTK animals 
compared with NaCl animals (Figure 9). Taken together, these findings indicate that MTK 
at the dose of 10 mg kg-1 actually has a somewhat toxic effect on certain cells in the 
brain of young mice. Another explanation could be that leukotrienes are important for 
the developing brain and hence affect the proliferation if they are inhibited.  
 
Figure 9. Number of Iba1+ cells in the granule cell layer. Two-way Anova showed a significant effect of the 
variables irradiation and drug treatment in the number of Iba1+ cells (F1,24 = 6.814, P = 0.0153; F1,24 = 5.873, 
P = 0.0233; respectively). Data are shown as mean ± S.E.M (N = 5-9 mice/group). Post-hoc Tukey results 
are indicated on the graphs: @ P < 0.05 for IR MTK versus control NaCl. Kalm M., Boström M., Eriksson Y. 
(2017). Unpublished data.  
 
In this occasion, it seems that MTK is also being toxic for microglia in control animals 
because MTK mice should be more or less at the same level as NaCl mice and in the IR 
group the levels of microglia should be higher because they are the key regulators of 
inflammation in the brain. However, preclinical safety data from the European 
Medicines Agency showed that signs of toxicity in animals were increased excretion of 
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saliva, gastrointestinal symptoms, loose stools and ion imbalance. These ocurred at 
dosages which provided more than 17-fold the systemic exposure seen at the clinical 
dosage. None of our treated mice showed any of these physiological symptoms. 
Furthermore, no deaths ocurred following a single oral administration of MTK at doses 
up to 5.000 mg kg-1 in mice, the maximum dose tested (60).  
In other neuroprotective agents it has been reported a bell-shaped dose-effect 
relationship against brain ischemia where above some doses the drug is ineffective. For 
example, it was observed that pranlukast had its maximal effect in improving 
neurological deficiency and inhibiting infarct volumes at 0.03 and 0.1 mg kg-1 (61). Also, 
for MTK it was showed its effectiveness at doses of 0.1 and 1.0 mg kg-1 in focal cerebral 
ischemic mice (62). Although the exact reasons are unclear it has been proposed that 
higher doses might cause cerebral vasoconstriction, reduction of blood pressure, and 
hypoglycaemia (61). In any case, in the study of pranlukast there are no analysis of its 
presence in serum, brain and CSF, being assumed (owing to previous experiments) that 
due to an accumulation of arachidonic acid and its products, such as LTC4, after ischemia 
a BBB dysfunction occurs which helps pranlukast going through. The same situation 
happens for the following experiment with MTK. Increased vascular permeability and 
BBB disruption after irradiation have been well documented. Data from Kalm et al. (63) 
shows that BBB permeability is increased 24 h after a single dose of 8 Gy to the young 
mouse brain. In our case it was a dose of 4 Gy administered twice, with an interval of 12 
h to avoid severe side-effects (55), and it has been reported that the increase in BBB 
permeability has a slow and delayed response, from weeks to months depending on the 
radiation dose, for fractionated RT compared to the single-dose IR (64) (65) . It is unclear 
to know when exactly the permeability increase of the BBB occurred, but even if it took 
place during the course of the experiment we must consider that in the article from 
where we extrapolated the dose the BBB was also disrupted because of 
neuroinflmmation and ageing. In behalf of that, we chose to administer the 10 mg kg-1 
body weight dose considering that the data demonstrate that MTK crosses the BBB at a 
therapeutic dose, and that age-dependent differential BBB integrity does not affect the 
capacity of MTK to enter the brain (52).  
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It is possible that this previously mentioned bell-shaped dose-effect is also the case of 
MTK and with the dose of 10 mg kg-1 used in this project we are beyond this bell-shaped 
curve so maybe we should try a lower dose. Furthermore, we are using young mice and 
this dose was extrapolated from a study performed on adult rats so there are some 
differences to consider, being the most important the species and then the contrast in 
weight and age.  
Moreover, in our experiment MTK was i.p. injected but it is and orally active agent and 
the evidence for its BBB penetrance with the used dose is based on oral administration; 
although pharmacokinetics of substances administered i.p. are more similar to those 
seen after oral administration than to parenteral route because they may undergo 
hepatic metabolism before reaching the systemic circulation (66). Thus, it would be 
advisable to assess the effect of MTK after the oral administration.   
Measuring the weight of the animals on a daily basis as a routine control we found out 
that, after IR, the ones treated with MTK did not lose as much weight as the NaCl mice 
(Figure 10) so MTK seems to be protecting against weight-loss after RT. It cannot be due 
to an increasing in the eating because control MTK are in the same weight as control 
NaCl, and at this age the mice are not weaned. Nonetheless more experiments would 
be required to investigate this point further.  
 
Figure 10. The mice were treated with either NaCl or montelukast for 14 days, starting 2 days before 
cranial radiotherapy. The weight was measured on a daily basis. 
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8. CONCLUDING REMARKS 
This thesis concludes that montelukast does not protect the brain from radiation-
induced neurotoxicity.  
 
Specific conclusions to given aims:  
I. MTK does not protect against OL loss in the CC after IR.  
 
II. MTK does not protect proliferating cells in the GCL after IR.  
 
III. MTK lowers the number of proliferating cells in the GCL regardless of IR.   
 
IV. MTK protects against acute weight-loss after IR in young mice.  
 
Finally, it would be necessary to perform more experiments using a lower dose with no 
toxic effects for the mice. For that, first it would be required to test MTK serum levels of 
young mice with a dose de-escalation to check that still pharmacologically resembles 
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